2 weeks Ago
Rhythm Pharmaceuticals, Inc. ( NASDAQ: RYTM ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants David Connolly - Head of Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Lee - Executive Vice President and Head of North America Yann Mazabraud - Executive Vice President and Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Philip Nadeau - TD Cowen Corinne Johnson - Goldman Sachs Group, Inc. Seamus Fernandez - Guggenheim Securities Dae Gon Ha - Stifel, Nicolaus & Company, Inc.
Whitney Ijem - Canaccord Genuity Corp. Jeff Hung - Morgan Stanley Tazeen Ahmad - Bank of America Merrill Lynch Joseph Stringer - Needham & Company Raghuram Selvaraju - H.C.
Wainwright & Co. Operator Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Third Quarter 2024 Earnings Conference Call.
At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, David Connolly, Head of Investor Relations and Corporate Communications. Please go ahead. David Connolly Thank you, Shannon.
I'm Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the Investors section of our website, ir.rhythmtx.
com. This afternoon, we issued our press release that provides our third quarter 2024 financial results and business update, and that press release is available on our website. We are coming to you today from San Antonio, the site of ObesityWeek, the annual meeting of The Obesity Society.
Listed on Slide 2 is our agenda. On the call today are David Meeker, our Chairman, Chief Executive Officer and President; Jennifer.
